Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Lung cancer represents one of the most prevalent malignant tumors globally, and its treatment has entered the era of targeted therapy. The epidermal growth factor receptor (EGFR) mutation is a common type of genetic mutation in non-small cell lung cancer (NSCLC), while c-ros oncogene 1 receptor tyrosine kinase (ROS-1) fusion mutation is a rare mutation site. Currently, there are few case reports on the coexistence of EGFR and ROS-1 gene mutations. This study reports a case of NSCLC with coexisting EGFR and ROS-1 gene mutations, aiming to provide relevant treatment strategies for clinical practice. .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257172 | PMC |
| http://dx.doi.org/10.3779/j.issn.1009-3419.2025.102.26 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Programmed Death Ligand-1 Expression and Its Determinants in Patients with Lung Cancer: A Tertiary Care Center Experience in India.
Ann Afr Med
August 2025
Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Background: Targeted therapy and immunotherapy have improved survival and quality of life in advanced lung cancer. In this study, we evaluated the frequency of programmed death ligand-1 (PDL-1) expression in lung cancer and its association with different clinical and histological subtypes.
Materials And Methods: It is a descriptive observational study, in which patients diagnosed with lung cancer were included.
[A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations in Non-small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi
June 2025
Kunming Medical University, Kunming 650500, China.
Lung cancer represents one of the most prevalent malignant tumors globally, and its treatment has entered the era of targeted therapy. The epidermal growth factor receptor (EGFR) mutation is a common type of genetic mutation in non-small cell lung cancer (NSCLC), while c-ros oncogene 1 receptor tyrosine kinase (ROS-1) fusion mutation is a rare mutation site. Currently, there are few case reports on the coexistence of EGFR and ROS-1 gene mutations.
View Article and Find Full Text PDF[Lung cancers with rare oncogenic drivers: RET, ROS-1, MET, HER2 and BRAF].
Bull Cancer
March 2025
Service de pneumologie, hôpital Larrey, CHU de Toulouse, Toulouse, France; Université Paul-Sabatier, Toulouse, France; Centre de recherche de cancérologie de Toulouse (CRCT), Inserm, Toulouse, France.
In non-small cell lung cancer, the presence of an oncogenic driver is frequently documented. Advances in molecular biology have enabled the identification of so-called rare oncogenic addictions, with an incidence of less than 5%, such as ROS-1 and RET rearrangements, and MET, BRAF and HER2 mutations. Targeted therapies have shown strong tumor responses with a better tolerance profile compared to chemotherapy.
View Article and Find Full Text PDFCase Series: EGFR and ROS-1 Co-Occurrence in Advanced Non-Small Cell Lung Cancer.
J Immunother Precis Oncol
November 2024
Department of Oncology, Princess Norah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
Non-small cell lung cancer (NSCLC) is a heterogeneous disease with diverse molecular alterations. Two of the most common genetic abnormalities found in advanced NSCLC are mutations in the epidermal growth factor receptor () and rearrangements in the ROS proto-oncogene 1 (). Although these two alterations are typically mutually exclusive, there have been reports of their co-occurrence in a small subset of NSCLC patients.
View Article and Find Full Text PDFPurpose: Next generation sequencing (NGS) testing is used to identify driver mutation(s) in non-small cell lung cancer (NSCLC) that are amenable to targeted therapy, resulting in superior outcomes and improved tolerability. We characterized how clinicians in a large integrated healthcare system utilized NGS testing to inform first line treatment decisions in patients with stage IV NSCLC shortly after diagnosis.
Methods: We conducted a cross-sectional study of 964 patients within an integrated healthcare system, Kaiser Permanente Southern California (KPSC), who were diagnosed with stage IV NSCLC and completed NGS testing (Strata Oncology) between May 2019 to June 2021.